SEC Company Response from Predictive Oncology Inc. (AGPU) (CIK 0001446159) (AGPU) — Oct 15, 2009

Predictive Oncology Inc. (AGPU) (CIK 0001446159)
Date: Oct. 15, 2009 · CIK: 0001446159 · Accession: 0001144204-09-053121

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-155299

Date

Oct. 15, 2009

Author

Chief

Form

CORRESP

Company

Predictive Oncology Inc. (AGPU) (CIK 0001446159)

Letter

BioDrain Medical, Inc.

Centre Pointe Boulevard, Suite 7

Mendota Heights, Minnesota 55120

October 15, 2009

VIA FACSIMILE AND EDGAR

Securities and Exchange Commission

450 Fifth Street, N. W.

Washington, D.C. 20549

Re:

BioDrain Medical, Inc.

Registration Statement – Form S-1 (Registration No. 333-155299)

Ladies and Gentlemen:

BioDrain Medical, Inc. (the “Company”) hereby requests that the Commission take appropriate action to cause the above-referenced registration statement on Form S-1 to become effective on October 19, 2009 at 9:00 a.m. Washington, D.C. time.

The Company hereby acknowledges the following:

should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

the company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very
truly yours,
BIODRAIN
MEDICAL, INC.

Show Raw Text

CORRESP
1
filename1.htm

    BioDrain
Medical, Inc.

    2060
Centre Pointe Boulevard, Suite 7

    Mendota
Heights, Minnesota 55120

    October
15, 2009

    VIA FACSIMILE AND
EDGAR

    Securities
and Exchange Commission

    450 Fifth
Street, N. W.

    Washington,
D.C. 20549

              Re:

              BioDrain
      Medical, Inc.

                Registration
      Statement – Form S-1 (Registration No.
  333-155299)

    Ladies
and Gentlemen:

    BioDrain
Medical, Inc. (the “Company”) hereby requests that the Commission take
appropriate action to cause the above-referenced registration statement on Form
S-1 to become effective on October 19, 2009 at 9:00 a.m. Washington, D.C.
time.

    The
Company hereby acknowledges the following:

              ·

              should
      the Commission or the staff, acting pursuant to delegated authority,
      declare the filing effective, it does not foreclose the Commission from
      taking any action with respect to the
filing;

              ·

              the
      action of the Commission or the staff, acting pursuant to delegated
      authority, in declaring the filing effective, does not relieve the company
      from its full responsibility for the adequacy and accuracy of the
      disclosure in the filing; and

              ·

              the
      company may not assert staff comments and the declaration of effectiveness
      as a defense in any proceeding initiated by the Commission or any person
      under the federal securities laws of the United
  States.

                  Very
      truly yours,

                  BIODRAIN
      MEDICAL, INC.

                  By:

                  /s/ Kevin Davidson

                  Kevin
      Davidson

                  Chief
      Executive
Officer

SecProbe.io